 | Up a level |
Ryom, L; Cotter, A; De Miguel, R; Béguelin, C; Podlekareva, D; Arribas, J R; Marzolini, C; Mallon, Pgm; Rauch, A; Kirk, O; Molina, J M; Guaraldi, G; Winston, A; Bhagani, S; Cinque, P; Kowalska, J D; Collins, S; Battegay, M (2020). 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV medicine, 21(10), pp. 617-624. Wiley 10.1111/hiv.12878
Hachfeld, Anna; Darling, K; Calmy, A; Ledergerber, B; Weber, R; Battegay, M; Wissel, K; Di Benedetto, C; Fux, C A; Tarr, P E; Kouyos, R; Ruggia, LS; Furrer, Hansjakob; Wandeler, Gilles (2019). Why do sub-Saharan Africans present late for HIV care in Switzerland? HIV medicine, 20(6), pp. 418-423. Blackwell Science 10.1111/hiv.12727
Kusejko, K; Marzel, A; Hampel, B; Bachmann, N; Nguyen, H; Fehr, J; Braun, D L; Battegay, M; Bernasconi, E; Calmy, A; Cavassini, M; Hoffmann, M; Böni, J; Yerly, S; Klimkait, T; Perreau, M; Rauch, Andri; Günthard, H F; Kouyos, R D (2018). Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland. HIV medicine, 19(10), pp. 688-697. Blackwell Science 10.1111/hiv.12660
Ryom, L; Boesecke, C; Bracchi, M; Ambrosioni, J; Pozniak, A; Arribas, J; Behrens, G; Mallon, Pgm; Puoti, M; Rauch, Andri; Miro, J M; Kirk, O; Marzolini, C; Lundgren, J D; Battegay, M (2018). Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. HIV medicine, 19(5), pp. 309-315. Blackwell Science 10.1111/hiv.12600
De Wit, S; Battegay, M; D'Arminio Monforte, A; Lundgren, J D; Oprea, C; Antinori, A; Bhagani, S; Fätkenheuer, G; Friis-Moller, N; Furrer, Hansjakob; Mussini, C (2018). European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16-17 November 2016: a summary. HIV medicine, 19(2), pp. 77-80. Blackwell Science 10.1111/hiv.12559
Marzel, A; Shilaih, M; Turk, T; Campbell, N K; Yang, W-L; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Furrer, Hansjakob; Calmy, A; Battegay, M; Cavassini, M; Bernasconi, E; Schmid, P; Metzner, K J; Günthard, H F; Kouyos, R D (2017). Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships. HIV medicine, 18(9), pp. 667-676. Blackwell Science 10.1111/hiv.12507
Erb, S; Letang, E; Glass, T R; Natamatungiro, A; Mnzava, D; Mapesi, H; Haschke, Manuel Martin; Duthaler, U; Berger, B; Muri, L; Bader, J; Marzolini, C; Elzi, L; Klimkait, T; Langewitz, W; Battegay, M (2017). Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems. HIV medicine, 18(9), pp. 623-634. Blackwell Science 10.1111/hiv.12499
Duthaler, U; Berger, B; Erb, S; Battegay, M; Letang, E; Gaugler, S; Krähenbühl, S; Haschke, Manuel Martin (2017). Automated high throughput analysis of antiretroviral drugs in dried blood spots. Journal of mass spectrometry, 52(8), pp. 534-542. Wiley 10.1002/jms.3952
Bader, J; Schöni-Affolter, F; Böni, J; Gorgievski, Meri; Martinetti, G; Battegay, M; Klimkait, T; Swiss HIV Cohort, Study (2016). Correlating HIV tropism with immunological response under combination antiretroviral therapy. HIV medicine, 17(8), pp. 615-622. Blackwell Science 10.1111/hiv.12365
Ryom, L; Boesecke, C; Gisler, Valentin; Manzardo, C; Rockstroh, J K; Puoti, M; Furrer, Hansjakob; Miro, J M; Gatell, J M; Pozniak, A; Behrens, G; Battegay, M; Lundgren, J D (2015). Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons. HIV medicine, 17(2), pp. 83-88. Blackwell Science 10.1111/hiv.12322
Hasse, Barbara; Tarr, Philip E; Marques-Vidal, Pedro; Waeber, Gerard; Preisig, Martin; Mooser, Vincent; Valeri, Fabio; Djalali, Sima; Rauch, Andri; Bernasconi, Enos; Calmy, Alexandra; Cavassini, Matthias; Vernazza, Pietro; Battegay, Manuel; Weber, Rainer; Senn, Oliver; Vollenweider, Peter; Ledergerber, Bruno; Aubert, V; Barth, J; ... (2015). Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. Open Forum Infectious Diseases, 2(3), ofv108. Oxford University Press 10.1093/ofid/ofv108
Rosin, C; Elzi, L; Thurnheer Zürcher, Maria Christine; Fehr, J; Cavassini, M; Calmy, A; Schmid, P; Bernasconi, E; Battegay, M (2015). Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study. HIV medicine, 16(5), pp. 319-325. Blackwell Science 10.1111/hiv.12203
Kouyos, Roger D; Hasse, Barbara; Calmy, Alexandra; Cavassini, Matthias; Furrer, Hansjakob; Stöckle, Marcel; Vernazza, Pietro L; Bernasconi, Enos; Weber, Rainer; Günthard, Huldrych F; Aubert, V; Battegay, M; Bernasconi, E; Böni, J; Bucher, H C; Burton-Jeangros, C; Calmy, A; Cavassini, M; Dollenmaier, G; Egger, M; ... (2015). Increases in Condomless Sex in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2(2), ofv077. Oxford University Press 10.1093/ofid/ofv077
Weber, R; Huber, M; Battegay, M; Stähelin, Cornelia Johanna; Castro Batanjer, E; Calmy, A; Bregenzer, A; Bernasconi, E; Schoeni-Affolter, F; Ledergerber, B (2015). Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. HIV medicine, 16(3), pp. 137-151. Blackwell Science 10.1111/hiv.12184
Clifford, G M; Lise, M; Franceschi, S; Egger, M; Bouchardy, C; Korol, D; Levi, F; Ess, S; Jundt, G; Wandeler, G; Fehr, J; Schmid, P; Battegay, M; Bernasconi, E; Cavassini, M; Calmy, A; Keiser, O; Schöni-Affolter, F; Swiss HIV Cohort Study, (2012). Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. British journal of cancer, 106(3), pp. 447-452. Basingstoke: Nature Publishing Group 10.1038/bjc.2011.558
Huber, M; Ledergerber, B; Sauter, R; Young, J; Fehr, J; Cusini, A; Battegay, M; Calmy, A; Orasch, C; Nicca, D; Bernasconi, E; Jaccard, R; Held, L; Weber, R; Swiss HIV Cohort Study Group, (2012). Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV medicine, 13(7), pp. 387-397. Oxford: Blackwell Science 10.1111/j.1468-1293.2011.00984.x
Gasser, O; Brander, C; Wolbers, M; Brown, N V; Rauch, A; Günthard, H F; Battegay, M; Hess, C; Swiss HIV Cohort Study, (2012). Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy. HIV medicine, 14(4), pp. 241-6. Oxford: Blackwell Science 10.1111/j.1468-1293.2012.01040.x
Stern, M; Czaja, K; Rauch, A; Rickenbach, M; Günthard, H F; Battegay, M; Fellay, J; Hirschel, B; Hess, C; Swiss HIV Cohort Study Group, (2012). HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption. HIV medicine, 13(10), pp. 589-95. Oxford: Blackwell Science 10.1111/j.1468-1293.2012.01019.x
Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, Hansjakob; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B; Swiss HIV Cohort Study, (SHCS) (2012). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV medicine, 14(4), pp. 195-207. Oxford: Blackwell Science 10.1111/j.1468-1293.2012.01051.x
Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R; Swiss HIV Cohort Study (SHCS), (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV medicine, 12(5), pp. 279-88. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00880.x
Young, J; Scherrer, A U; Günthard, Hf; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, Ca; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, Hc; Swiss HIV Cohort Study, (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV medicine, 12(5), pp. 299-307. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00885.x
Babouee, B; Widmer, A F; Dubuis, O; Ciardo, D; Droz, S; Betsch, B Y; Garzoni, C; Führer, U; Battegay, M; Frei, R; Goldenberger, D (2011). Emergence of four cases of KPC-2 and KPC-3-carrying Klebsiella pneumoniae introduced to Switzerland, 2009-10. Euro surveillance, 16(11) Saint-Maurice: Institut de Veille Sanitaire
Bucher, HC; Richter, W; Glass, TR; Magenta, L; Wang, Q; Cavassini, M; Vernazza, P; Hirschel, B; Weber, R; Furrer, H; Battegay, M; Bernasconi, E (2011). Small dense lipoproteins, apolipoprotein B and risk of coronary events in HIV-infected patients on antiretroviral therapy. Journal of acquired immune deficiency syndromes JAIDS, 60(2), pp. 135-142. Philadelphia, Pa.: Lippincott Williams & Wilkins 10.1097/QAI.0b013e31824476e1
Combescure, Christophe; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV medicine, 10(8), pp. 470-6. Oxford: Blackwell Science 10.1111/j.1468-1293.2009.00714.x
Wolbers, M; Bucher, H C; Furrer, H; Rickenbach, M; Cavassini, M; Weber, R; Schmid, P; Bernasconi, E; Hirschel, B; Battegay, M (2008). Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV medicine, 9(6), pp. 397-405. Oxford: Blackwell Science 10.1111/j.1468-1293.2008.00566.x
Nguyen, A; Calmy, A; Schiffer, V; Bernasconi, E; Battegay, M; Opravil, M; Evison, J-M; Tarr, P E; Schmid, P; Perneger, T; Hirschel, B (2008). Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV medicine, 9(3), pp. 142-50. Oxford: Blackwell Science 10.1111/j.1468-1293.2007.00537.x
The, Antiretroviral Therapy (ART) Cohort Collaboration; Sterne, JA; May, M; Sabin, C; Phillips, A; Costagniola, D; Chêne, G; Justice, AC; De Wolf, F; Hogg, R; Battegay, M; D'Arminio Monforte, A; Fätkenheuer, G; Staszewski, S; Gill, J; Egger, M (2007). Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy. Journal of acquired immune deficiency syndromes JAIDS, 46(5), pp. 607-615. Philadelphia, Pa.: Lippincott Williams & Wilkins
Wolbers, M; Opravil, M; von Wyl, V; Hirschel, B; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M; Yerly, S; Günthard, H; Bucher, HC; Swiss, HIV Cohort Study (2007). Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS, 21(16), pp. 2201-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/QAD.0b013e3282efacb1
Simcock, M; Blasko, M; Karrer, U; Bertisch, B; Pless, M; Blumer, L; Vora, S; Robinson, JO; Bernasconi, E; Terziroli, B; Moirandat-Rytz, S; Furrer, H; Hirschel, B; Vernazza, P; Sendi, P; Rickenbach, M; Bucher, HC; Battegay, M; Koller, MT and Swiss, HIV Cohort Study (2007). Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral therapy, 12(6), pp. 931-9. London: International Medical Press
Wolbers, M; Battegay, M; Hirschel, B; Furrer, H; Cavassini, M; Hasse, B; Vernazza, PL; Bernasconi, E; Kaufmann, G; Bucher, HC; Swiss, HIV Cohort Study (2007). CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antiviral therapy, 12(6), pp. 889-97. London: International Medical Press
von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, PL; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, HF; for, the Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of internal medicine, 167(16), pp. 1782-90. Chicago, Ill.: American Medical Association 10.1001/archinte.167.16.1782
Glass, TR; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC; Swiss, HIV Cohort Study (2007). Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. HIV clinical trials, 8(2), pp. 77-85. St. Louis, Mo.: Thomas Land Publishers 10.1310/hct0802-77
Glass, TR; Ungsedhapand, C; Wolbers, M; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC; Swiss, HIV Cohort Study (2006). Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV medicine, 7(6), pp. 404-10. Oxford: Blackwell Science 10.1111/j.1468-1293.2006.00400.x
Zinkernagel, AS; von Wyl, V; Ledergerber, B; Rickenbach, M; Furrer, H; Battegay, M; Hirschel, B; Tarr, PE; Opravil, M; Bernasconi, E; Schmid, P; Weber, R; Swiss, HIV Cohort Study (2006). Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy, 11(2), pp. 131-42. London: International Medical Press
Karrer, U; Ledergerber, B; Furrer, H; Elzi, L; Battegay, M; Cavassini, M; Gayet-Ageron, A; Hirschel, B; Schmid, P; Russotti, M; Weber, R; Speck, RF; Swiss, HIV Cohort Study (2005). Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS, 19(17), pp. 1987-94. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.aids.0000194136.73876.9c
Schüpbach, J; Günthard, H; Joos, B; Fischer, M; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B; Swiss, HIV Cohort Study (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes JAIDS, 40(3), pp. 250-6. Philadelphia, Pa.: Lippincott Williams & Wilkins
Young, J; Weber, R; Rickenbach, M; Furrer, H; Bernasconi, E; Hirschel, B; Tarr, PE; Vernazza, P; Battegay, M; Bucher, HC (2005). Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antiviral therapy, 10(5), pp. 585-91. London: International Medical Press
Kaufmann, GR; Furrer, H; Ledergerber, B; Perrin, L; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Rickenbach, M; Hirschel, B; Battegay, M; Swiss, HIV Cohort Study (2005). Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases, 41(3), pp. 361-72. Cary, N.C.: The University of Chicago Press 10.1086/431484
Tarr, PE; Taffé, P; Bleiber, G; Furrer, H; Rotger, M; Martinez, R; Hirschel, B; Battegay, M; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Rickenbach, M; Ledergerber, B; Telenti, A; Swiss, HIV Cohort Study (2005). Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. Journal of infectious diseases, 191(9), pp. 1419-26. Cary, N.C.: The University of Chicago Press 10.1086/429295
Young, J; Rickenbach, M; Weber, R; Furrer, H; Bernasconi, E; Hirschel, B; Tarr, PE; Vernazza, P; Battegay, M; Bucher, HC (2005). Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antiviral therapy, 10(1), pp. 73-81. London: International Medical Press
